CHEMOCENTRYX INC (CCXI)       51.99  +0.03 (+0.06%)

51.99  +0.03 (+0.06%)

US16383L1061 - Common Stock - After market: 51.99 0 (0%)


Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CCXI. CCXI was compared to 641 industry peers in the Biotechnology industry. CCXI scores bad on very profitability, while its financial health is fine. Not spectacular, but in line with the averages. CCXI is valued quite expensive, but it does show an excellent growth.




Profitability

Profitability Rating

1

The profitability ratios for CCXI are negative, so there is not much use analyzing them.
CCXI's Return On Assets of -31.74% is worse than the rest of the industry. The industry average Return On Assets is 12.39%. 100% of the industry peers have a better Return On Assets.

CCXI has a Profit Margin of -357.01%. This is below the industry average of 27.64%. 100% of the industry peers outperform CCXI.
CCXI has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of CCXI.
VS Industry

ROA (-31.74%) VS Industry: 0% outperformed.

0.11
52.28

Profit Margin (-357.01%) VS Industry: 0% outperformed.

0.84
1,971.30

Valuation

Valuation Rating

0

The Price/Earnings Ratio is negative for CCXI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CCXI. No positive earnings are expected for the next year.

When comparing the current price to the book value of CCXI, we can conclude it is valued rather expensively. It is trading at 15.68 times its book value.
Compared to an average industry price book ratio of 1.89, CCXI is valued more expensive than its industry peers. 96% of the companies listed in the same industry are valued cheaper.
VS Industry

Price/Book (15.68) VS Industry: 4% outperformed.

448.49
0.07

Growth

Growth Rating

9

CCXI is expected to show a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 47.34% yearly.
CCXI shows a strong growth in Revenue. In the last year, the Revenue has grown by 72.49%.
Measured over the past 5 years, CCXI shows a very strong growth in Revenue. The Revenue has been growing by 21.96% on average per year.

CCXI is expected to show a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 134.59% yearly.
The Revenue growth is accelerating: in the next 5 years the growth will be better than in the last years.
The earnings per share for CCXI have decreased by -6.78% in the last year.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -6.78% 9.69% 37.13% 41.06% 47.34%
Revenue21.96% -9.08% 72.49% 117.77% 157.52% 130.02% 134.59%

Health

Health Rating

6

CCXI has a Current Ratio of 4.54. This indicates that CCXI is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 4.47 indicates that CCXI has no problem at all paying its short term obligations.
CCXI has an Altman-Z score of 9.70. This indicates that CCXI is financially healthy and little risk of bankruptcy at the moment.
The Altman-Z score of CCXI is much better than the industry average of -0.10. CCXI has a better rating than 85% of its industry peers.

When comparing the Debt to Equity Ratio of CCXI to the average industry Debt to Equity Ratio of 0.00, CCXI required more debt to finance its operations than its industry peers.
We won't put much weight on the industry comparison as CCXI has a very low Debt to Equity (0.02).
When comparing the Current Ratio of CCXI to the average industry Current Ratio of 6.18, CCXI is less able to pay its short term obligations than its industry peers.
When comparing the Quick Ratio of CCXI to the average industry Current Ratio of 6.05, CCXI is less able to pay its short term obligations than its industry peers.
The Piotroski-F score of CCXI is 3.00. This is a low score and indicates issues in the health and profitability of CCXI.
VS Industry

Debt/Equity (0.02) VS Industry: 33% outperformed.

15.37
0.00

Quick Ratio (4.47) VS Industry: 37% outperformed.

0.04
84.53

Current Ratio (4.54) VS Industry: 37% outperformed.

0.08
85.09

Altman-Z (9.7) VS Industry: 85% outperformed.

-2,801.75
658.20

Dividend

Dividend Rating

0

No dividends for CCXI!.

CHEMOCENTRYX INC51.99

NASDAQ:CCXI (10/19/2022, 7:04:24 PM)+0.03 (+0.06%)

After market: 51.99 0 (0%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 08-08 2022-08-08/amc Earnings (Next) 11-08 2022-11-08/amc
Inst Owners 78.02% Inst Owner Change -5.07%
Ins Owners 0.1% Ins Owner Change -4185.44%
Market Cap 3.71B Analysts 52.31
Price Target 53.04 (2.02%)

Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y) N/A DP N/A
Div Incr Years N/A Div Non Decr Years N/A
Ex-Date N/A

Surprises & Revisions
EPS beat(2) 1 Avg EPS beat(2) -30.65%
Min EPS beat(2) -73.94% Max EPS beat(2) 12.63%
EPS beat(4) 3 Avg EPS beat(4) -7.25%
Min EPS beat(4) -73.94% Max EPS beat(4) 29.7%
Revenue beat(2) N/A Avg Revenue beat(2) -41.92%
Min Revenue beat(2) -74.96% Max Revenue beat(2) -8.87%
Revenue beat(4) 1 Avg Revenue beat(4) -25.25%
Min Revenue beat(4) -74.96% Max Revenue beat(4) 29.07%
PT rev (1m) N/A PT rev (3m) N/A
EPS NQ rev (1m) N/A EPS NQ rev (3m) N/A
EPS NY rev (1m) N/A EPS NY rev (3m) N/A
Revenue NQ rev (1m) N/A Revenue NQ rev (3m) N/A
Revenue NY rev (1m) N/A Revenue NY rev (3m) N/A

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 99.51
P/FCF N/A
P/OCF N/A
P/B 15.68
P/tB 15.68
EV/EBITDA -26.68
EPS(TTM) -1.89 EY N/A
EPS(NY) -0.23 Fwd EY N/A
FCF(TTM) -0.83 FCFY N/A
OCF(TTM) -0.75 OCFY N/A
SpS 0.52 BVpS 3.31
TBVpS 3.32 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA -31.74%
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -353.17%
PM -357.01%
GM N/A
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y N/A GM growth 5Y N/A
F-Score 3 Asset Turnover 0.09

Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 134.75%
Profit Quality N/A
Current Ratio 4.54
Quick Ratio 4.47
Altman-Z 9.7
F-Score 3 WACC 9.62%
ROIC/WACC N/A Cap/Depr(3y) 860.12%
Cap/Depr(5y) 583.3% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y -6.78% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 21.43%
EPS Next Y 9.69% EPS Next 2Y 37.13%
EPS Next 3Y 41.06% EPS Next 5Y 47.34%
Revenue growth 1Y 72.49% Revenue growth 3Y -9.08%
Revenue growth 5Y 21.96% Revenue growth Q2Q 548.81%
Revenue Next Year 117.77% Revenue Next 2Y 157.52%
Revenue Next 3Y 130.02% Revenue Next 5Y 134.59%
EBIT growth 1Y N/A EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year N/A
EBIT Next 3Y N/A EBIT Next 5Y N/A
FCF growth 1Y 30.95% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y 35.33%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA